Asset Acquisition Consideration Transferred, Liabilities

No definition available.

Name:	avtx_AssetAcquisitionConsiderationTransferredLiabilities
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Agreement, Milestone Payment

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeAgreementMilestonePayment
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, License Rights Royalty Percentage

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementLicenseRightsRoyaltyPercentage
Namespace Prefix:	avtx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement Rights And Obligations License Fee

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsLicenseFee
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Upfront Fee

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Royalty Term

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRoyaltyTerm
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Termination Notice

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementTerminationNotice
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent Milestone Payment

+ References

No definition available.

+ Details

Name:	avtx_ContingentMilestonePayment
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contingent Milestone Upfront Payment Percentage

+ References

No definition available.

+ Details

Name:	avtx_ContingentMilestoneUpfrontPaymentPercentage
Namespace Prefix:	avtx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer, License Agreement Expiration Term

+ References

No definition available.

+ Details

Name:	avtx_ContractWithCustomerLicenseAgreementExpirationTerm
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer, Revenue Recognized to Date From Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum Potential Payments

+ References

No definition available.

+ Details

Name:	avtx_MaximumPotentialPayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments
Namespace Prefix:	avtx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Agreement, Payment Received

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementPaymentReceived
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty Agreement, Period After Public Launch To Terminate Agreement

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payment Paid

+ References

No definition available.

+ Details

Name:	avtx_UpfrontPaymentPaid
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for the settlement of litigation or for other legal issues during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForLegalSettlements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=avtx_AlmataBioTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX301OutLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX009Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_LillyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX009LillyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX002KKCLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_CHOPLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AstellasPharmaIncAstellasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX006Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX006AstellasLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AltoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_ESMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AUGTherapeuticsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_PurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX800SeriesAssetSaleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details)								1 Months Ended			12 Months Ended
Commitments and Contingencies (Details)	Mar. 28, 2024 USD ($)	Mar. 27, 2024 USD ($)	Oct. 27, 2023 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Feb. 03, 2020 USD ($)	Jul. 15, 2019 USD ($)	Oct. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)	Jul. 31, 2019 USD ($)	Dec. 31, 2025 USD ($)	Jun. 09, 2021 USD ($)
Loss Contingencies [Line Items]
Royalty agreement, payment received										$ 2,000,000.0
Period after public launch to terminate agreement										3 years
Buyout option, percentage of net present value of royalty payments										75.00%
AlmataBio Transaction
Loss Contingencies [Line Items]
Cash payments to acquire assets	$ 7,500,000								$ 7,500,000		$ 7,500,000
AVTX-301 Out-License
Loss Contingencies [Line Items]
Licensed product expiration term				10 years
Milestone One \| AlmataBio Transaction
Loss Contingencies [Line Items]
Contingent consideration	5,000,000.0
Milestone Two \| AlmataBio Transaction
Loss Contingencies [Line Items]
Contingent consideration	$ 15,000,000.0
Milestone Three \| AVTX-009
Loss Contingencies [Line Items]
Collaborative agreement, milestone payment								$ 5,000,000.0
Lilly License Agreement \| AVTX-009 Lilly License Agreement
Loss Contingencies [Line Items]
Milestone payments		$ 70,000,000.0
Maximum aggregate milestone payment		$ 650,000,000.0
License agreement term		120 days
Research and development											0
Cumulative expense recognized to date											0
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Minimum
Loss Contingencies [Line Items]
License agreement royalties		5.00%
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Maximum
Loss Contingencies [Line Items]
License agreement royalties		15.00%
Kyowa Kirin Co., Ltd. (KKC) \| Minimum \| Contract Termination
Loss Contingencies [Line Items]
License agreement term					6 months
Kyowa Kirin Co., Ltd. (KKC) \| Maximum \| Contract Termination
Loss Contingencies [Line Items]
License agreement term					12 months
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Loss Contingencies [Line Items]
Research and development											0
Cumulative expense recognized to date											0
Upfront license fee					$ 10,000,000.0
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Loss Contingencies [Line Items]
Maximum aggregate milestone payment					112,500,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Loss Contingencies [Line Items]
Maximum aggregate milestone payment					$ 75,000,000.0
CHOP License Agreement
Loss Contingencies [Line Items]
Collaborative arrangement, royalty term						15 years
CHOP License Agreement \| Contract Termination
Loss Contingencies [Line Items]
License agreement term						6 months
CHOP License Agreement \| AVTX-002 KKC License Agreement
Loss Contingencies [Line Items]
Maximum aggregate milestone payment											1,300,000
Upfront license fee						$ 500,000
Payments for legal settlements						1,000,000.0
License fee						$ 200,000
Astellas Pharma, Inc. (Astellas)
Loss Contingencies [Line Items]
License agreement term							60 days
Astellas Pharma, Inc. (Astellas) \| AVTX-006
Loss Contingencies [Line Items]
Licensed product expiration term							10 years
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Loss Contingencies [Line Items]
Maximum aggregate milestone payment							$ 5,500,000
Research and development											0
Cumulative expense recognized to date											500,000
Upfront license fee							$ 500,000
Alto \| AVTX-301 Out-License
Loss Contingencies [Line Items]
Maximum proceeds from milestones				$ 18,600,000
Revenue recognized from milestones to date											0
ES \| AVTX-406 License Assignment
Loss Contingencies [Line Items]
Revenue recognized from milestones to date											$ 0
ES \| Milestone One \| AVTX-406 License Assignment
Loss Contingencies [Line Items]
Maximum proceeds from milestones												$ 6,000,000.0
ES \| Milestone Two \| AVTX-406 License Assignment
Loss Contingencies [Line Items]
Maximum proceeds from milestones												$ 20,000,000.0
AUG Therapeutics, LLC \| Purchase Agreement \| AVTX-800 Series Asset Sale
Loss Contingencies [Line Items]
Upfront payment paid			$ 200,000
Asset acquisition consideration transferred, liabilities			$ 400,000
Contingent milestone upfront payment percentage			0.20
Contingent milestone payment			$ 15,000,000.0
Maximum potential payments			$ 45,000,000.0